Siew Choo Su Malaysia

Consultant Paediatrician and Paediatric Respiratory Physician
Job Title
Consultant Paediatrician and Paediatric Respiratory Physician
Faculty / Department / Division
Department of Paediatrics
Institution / Organisation
Pantai Hospital Kuala Lumpur

19 November 2026, Thursday

Time Session
08:30
13:00
Naricha Chirakalwasan Chairperson Thailand
Rashidah Yasin Chairperson Malaysia
Function Room 8, Ground Mezzanine Floor

20 November 2026, Friday

Time Session
09:30
11:00
Lalitha Pereirasamy Chairperson Malaysia
Umadevi A. Muthukumaru Chairperson Malaysia
  • Ernest Mau Ern Poh Speaker Malaysia
  • Anne Chang Speaker Australia
    "Therapeutic Advances in Bronchiectasis: Prof Anne B Chang Queensland University of Technology; Department of Respiratory and Sleep Medicine, Queensland Children’s Hospital, Brisbane; and Menzies School of Health Research, Darwin, Australia Bronchiectasis is coming of age with the realisation of its burden of disease on patients and health systems, combined with increased research and pharmaceutical interest with fresh therapeutics. Early therapeutics focused on using antibiotics. While the first use of inhaled antibacterial solutions for bronchiectasis occurred in 1892[1], specific inhaled antibiotics usage was initially extrapolated from CF data in the 1990s until the first RCT that targeted adults with bronchiectasis.[2] Treatment of bronchiectasis has advanced markedly since the adoption of Cole’s paradigm,[3] which has now evolved into the contemporary vortex model. Using this framework, therapeutic advances include optimised airway clearance strategies, long-term macrolide therapy, inhaled and systemic antibiotics for selected patients, and improved treatment pathways for exacerbations and chronic infection, rehabilitation, muco-active agents (for a subset) as well as specific treatment for different phenotypes.[4] Both neutrophil dominant and eosinophil phenotypes have emerged as a leading therapeutic focus. These have culminated in the development of a therapeutic pipeline of dipeptidyl peptidase 1 (DPP 1) inhibitors including brensocatib, verducatib and HSK31858. Together, these interventions have reduced exacerbation frequency and improved quality of life in appropriately selected patients, and DPP 1 has a disease-modifying effect. In parallel, greater attention is being given to nutrition, vaccination, comorbidities, and adherence to self-management plans, all of which contribute to treatment effectiveness. With respect to antibiotics, several pharmaceutical companies undertook large multicenter RCTs (e.g. AIR-BX, RESPIRE, ORBIT). Despite demonstrating reductions in airway bacterial load, these trials yielded mixed results for their primary clinical endpoints (mostly exacerbations).[5] While possible explanation for the variance include the heterogeneity in microbiome baseline status and geography[5], the latest systematic review (20 RCTs) generally favoured inhaled antibiotics (vs placebo) with reduced exacerbation frequency (RR=0.78, 95%CI 0.68, 0.91) and improved and QoL-Bronchiectasis respiratory symptom score (mean difference=2.51, 95%CI 0.44-4.31).[6] Bronchiectasis management has thus evolved from symptom control toward a more targeted approach. Emerging strategies are increasingly focused on precision medicine, including better risk stratification, biomarker development, and use of imaging and microbiologic data to guide therapy. Overall, therapeutic progress in bronchiectasis reflects a shift toward earlier intervention, prevention of exacerbations, and more personalized care. Despite these advances, important gaps remain in pediatric bronchiectasis, where high-quality evidence is still limited and most treatment decisions are extrapolated from adult data. References 1 Osler W. The principles and practice of medicine: designed for the use of practitioners and students of medicine. New York: D. Appleton and Company, 1892. 2 Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162: 481-485. 3 Cole PJ. Inflammation: a two edged sword. The model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147: 6-15. 4 Tramontano A, Caporaso M, Macciocchi G, et al. New Perspectives in the Treatment of Bronchiectasis. Arch Bronconeumol 2026; Jan 9:S0300-2896(26)00004-9. 5 Mac Aogain M. Beyond ORBIT: Mapping the Constellation of Pseudomonas Endotypes in Bronchiectasis Clinical Trials. Am J Respir Crit Care Med 2025; 211: 1321-1323. 6 Cordeiro R, Choi H, Haworth CS, et al. The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults: Updated Systematic Review and Meta-Analysis. Chest 2024; 166: 61-80. "
  • Herbert Wang Chun Kwok Speaker Hong Kong
    Co-morbidities are highly prevalent in non-cystic fibrosis bronchiectasis and serve as major drivers of disease severity, healthcare utilization, and mortality. While traditional clinical assessments focus primarily on pulmonary architecture, emerging evidence demonstrates that multimorbidity profoundly impacts patient prognosis, necessitating a shift toward comprehensive, multi-organ evaluation. This talk synthesizes current global registry data and international cohorts to examine the prevalence, pathophysiological mechanisms, and prognostic implications of respiratory, systemic, and psychological co-morbidities. Concomitant airway diseases such as COPD and asthma independently predict increased exacerbation frequency, accelerated FEV1 decline, and reduced survival, while chronic rhinosinusitis correlates with altered airway microbiology and type 2 inflammation. Systemic and metabolic complications—including diabetes mellitus, Vitamin D deficiency, and gastroesophageal reflux managed with high-dose proton pump inhibitors—are heavily associated with worse radiological severity, increased hospitalizations, and elevated all-cause mortality. Furthermore, bronchiectasis significantly escalates the risk of cardiovascular events and progressive renal decline, where renal impairment independently triples mortality risk. Dedicated risk stratification tools, such as the Bronchiectasis Aetiology Comorbidity Index (BACI), outperform generic comorbidity indices in predicting long-term survival. Recognizing, screening, and actively managing these extra-pulmonary and overlapping conditions is essential for delivering personalized care and improving long-term patient outcomes.
  • Q&A
Ballroom 3, Lower Ground Floor
11:00
12:00
Aisya Natasya Musa Chairperson Malaysia
Diahn-Warng Perng Chairperson Taiwan
  • Azza Omar Speaker Malaysia
  • Anthony Yii Speaker Singapore
    Acute asthma exacerbations are conventionally treated with a standard course of systemic corticosteroids, regardless of the underlying inflammatory phenotype. However, increasing evidence suggests that exacerbations are biologically heterogeneous, with differences in corticosteroid responsiveness between type 2-high and type 2-low inflammation. Repeated corticosteroid exposure also contributes to substantial long-term morbidity and healthcare costs. This presentation examines the rationale and emerging evidence for biomarker-directed treatment of acute asthma exacerbations. Transcriptomic studies demonstrate differential corticosteroid effects across inflammatory pathways, while clinical studies suggest that physiological responses may vary according to inflammatory phenotype. Findings from a randomized controlled trial evaluating blood eosinophil-guided corticosteroid duration in hospitalized asthma exacerbations will be presented, alongside emerging evidence for biologic therapies during acute exacerbations. Together, these findings support a shift towards more individualized exacerbation management, with the potential to reduce unnecessary corticosteroid exposure while maintaining clinical effectiveness. Larger confirmatory trials are needed before widespread implementation.
  • Peter Gibson Speaker Australia
  • Q&A
Ballroom 1, Lower Ground Floor
Chee Kuan Wong Chairperson Malaysia
Fatimah Azmah Mohammad Chairperson Malaysia
  • Min Suk Yang Speaker Republic of Korea
    Asthma is not a single disease. Cluster and molecular studies consistently identify a type 2-high endotype, driven by epithelial alarmins, IL-4, IL-5 and IL-13, whereas type 2-low asthma remains poorly defined. Blood eosinophils and FeNO each predict exacerbations independently of clinical risk factors, and together identify the highest-risk patients. Because corticosteroids suppress both, low values on treatment should be repeated before a patient is labelled type 2-low. Six monoclonal antibodies target IgE, IL-5 or its receptor, IL-4Rα and TSLP. All reduce exacerbations, and several spare oral corticosteroids, yet registries show clinical remission in only one in four or five patients, and cost shapes real-world use. With no overall winner, the choice rests on predictive biomarkers and comorbidities. Beyond the blood count, CT mucus plugs, exacerbation phenotyping, molecular profiling and treatable traits are extending precision care, with remission, more likely before steroid dependence, as the goal.
  • Takao Fujisawa Speaker Japan
    Childhood wheeze encompasses heterogeneous clinical courses with different implications for subsequent asthma. Birth cohorts, including Tucson, ALSPAC, and PIAMA, have established the importance of wheeze timing and persistence. However, heterogeneity among infants who already have recurrent wheeze remains less well characterized. This presentation reviews these cohort frameworks and examines how the Phenotyping of Wheezing Infants (P-WIN) study extends trajectory analysis by incorporating episode frequency. P-WIN enrolled 253 children aged 12–23 months with recurrent wheeze across 27 Japanese sites. Monthly caregiver reports supported longitudinal assessment, and 219 children completed follow-up to age three. Latent class growth analysis of annual wheeze episode counts identified four trajectories: early resolving (24.2%), low frequency with a mid-course peak (57.1%), persistent high frequency (12.8%), and late-peaking high frequency (5.9%). The two high-frequency groups comprised 18.7% of participants and experienced greater symptom burden. Household exposures, including parental smoking, showed associations with trajectory membership, although these observational findings do not establish causality. These results demonstrate clinically relevant variation in wheeze frequency and timing within an already symptomatic population. Nevertheless, trajectory membership depends on subsequent observations, and its value for baseline prediction, treatment selection, and school-age prognosis requires validation. In relation to “The Evolving Immune Landscape,” P-WIN provides a clinical framework for future mechanistic investigation. Immune assessment was limited to routine IgE and eosinophil measurements, and the study did not identify immune endotypes. Repeated immune profiling could test how type 2 immunity and antiviral, epithelial, or neutrophilic pathways relate to evolving wheeze patterns. Integrating these measurements with longitudinal symptoms and school-age asthma and lung function outcomes may clarify the biological and prognostic significance of early wheeze trajectories.
  • Jessie Anne De Bruyne Speaker Malaysia
    Preschool wheezing and childhood asthma are common conditions which are still poorly understood due to the heterogeneity of the underlying pathological mechanisms and the time course of the disease development together with the variable connection between the two. Current diagnostic labels which have evolved over time are imprecise as clinical presentations are often similar across different underlying mechanisms and diagnostic tests are not only lacking but can be difficult in young children leading to difficulties in targeting therapy. Modern data approaches encompass machine learning (computers learning from data), artificial intelligence (smart computer systems), data science (analysing large numbers of medical records) and big data (combining blood tests, genes, clinical history, and scans). Carefully designed epidemiological and birth cohort studies have collected "big data" on a large scale, with a wealth of longitudinal clinical data and detailed information from various modalities including imaging, biomarkers, respiratory function testing among others have sought to address this conundrum of preschool wheeze and childhood asthma.
  • Q&A
Ballroom 4, Lower Ground Floor
14:00
15:00
Albert M. Li Chairperson Hong Kong
Siew Choo Su Chairperson Malaysia
  • Anne Chang Speaker Australia
    "Bronchiectasis exacerbations remain a significant cause of morbidity in children, associated with increased symptom burden, reduced quality of life, and recurrent health care utilisation and future lung function deterioration. Growing evidence indicates that exacerbation risk is shaped by a combination of clinical, microbiological, and radiological factors rather than by a single determinant. Previous exacerbation frequency, prior hospitalisation, younger age at presentation, chronic bacterial infection, and more extensive structural lung disease have all been associated with a higher likelihood of subsequent events. Although prediction is still imprecise at the individual level, these features may help define a higher-risk phenotype that can support closer surveillance and earlier intervention. Our recent work showed that the ‘daily wet-cough dominant’ and ‘Wheeze Dyspnoea’ phenotypes were associated with increased risk of hospitalisations post-recruitment. We have also identified six neutrophil-associated genes were associated with a future exacerbation, suggesting that peripheral blood gene expression may help identify children at risk of exacerbations. Prevention strategies are more established and include regular airway clearance, prompt treatment of wet cough episodes, vaccination, nutritional support, and individualized action plans. In selected children, long-term macrolide therapy may reduce exacerbation frequency, while careful follow-up and early intervention can limit progression. Overall, the current evidence supports a risk-stratified approach that combines clinical assessment with proactive management. We need future research that use validated paediatric prediction tools that integrate clinical, microbiologic, and imaging data to better guide prevention and treatment. "
  • Anna Marie Nathan Speaker Malaysia
    "Long Term prognosis of Chronic Suppurative Lung Disease Prof Dr Anna Marie Nathan Non-CF Bronchiectasis (NCFBE) and CSLD are the leading causes of BE in Asia. Recent interest has moved NCFBE out of the “orphan” disease category. Paediatric bronchiectasis is reversible with timely diagnosis and effective treatment (1). However, data on the ideal management of NCFBE remain limited, with a limited armamentarium of treatment options, especially in children, where randomised trials are severely lacking 1. We have published data on children with CSLD/BE 2. Seventy-eight per cent of children who performed spirometry had values <80% of the normal predicted value. Anthropometric measurements in children with NCFBE were static despite treatment. PC-QOL scores were low 2. A study from Thailand found that pulmonary exacerbation occurred in 80% of children, with a higher rate in non-infectious bronchiectasis than postinfectious bronchiectasis (90.9% vs 61.5%, p = 0.036). Hospitalisation was required for 77.1% of children, with a higher rate of non-infectious bronchiectasis than postinfectious bronchiectasis (86.3% vs 53.8%, p = 0.033) 3. Seventy-seven per cent of interviewed parents had abnormal DASS21 scores, with 54% being stressed and 51% being depressed. Parents of children diagnosed with CF had significantly lower DASS21 scores, hence indicating better mental health scores compared to non-CF CSLD 2. The presence of Pseudomonas aeruginosa (Pa) in the airways of patients with non-CF bronchiectasis has been associated with accelerated lung function decline and increased morbidity and mortality. Guidelines suggest inhaled antibiotics to promote eradication 1(1). We have found that eradication is associated with improved quality-of-life outcomes, with significant improvements in PC-QoL scores and cough scores after 3 months of treatment observed in patients who received both systemic and inhaled antibiotics (P = 0.002 and P = 0.003, respectively), but not in patients who received inhaled antibiotics alone (P = 0.09 and P = 0.89, respectively 4. In a study examining long-term outcomes of childhood bronchiectasis, young adults with bronchiectasis rarely attended adult respiratory clinics despite being symptomatic and having multiple emergency doctor visits5. This reflects inefficient transition programmes for our patients, which will translate to very poor adult outcomes. References 1.Chang, A. B., Fortescue, R., Grimwood, K., Alexopoulou, E., Bell, L., Boyd, J., Bush, A., Chalmers, J. D., Hill, A. T., Karadag, B., Midulla, F., McCallum, G. B., Powell, Z., Snijders, D., Song, W. J., Tonia, T., Wilson, C., Zacharasiewicz, A., & Kantar, A. (2021). European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. The European respiratory journal, 58(2), 2002990. https://doi.org/10.1183/13993003.02990-2020 2. Nathan, A. M., Muthusamy, A., Thavagnanam, S., Hashim, A., & de Bruyne, J. (2014). Chronic suppurative lung disease in a developing country: impact on child and parent. Pediatric pulmonology, 49(5), 435–440. https://doi.org/10.1002/ppul.23001 3.Sitthikarnkha P, Anekvorakul A, Niamsanit S, Techasatian L, Saengnipanthkul S, Uppala R. Clinical characteristics and outcome of non-cystic fibrosis bronchiectasis in children: A tertiary care perspective. SAGE Open Med. 2025 Feb 19;13:20503121251320849. doi: 10.1177/20503121251320849. PMID: 39980590; PMCID: PMC11840848 4. Goh WT, Hng SY, Azanan MS, Eg KP, Adam Q, Lee QY, et al. Utility of inhaled antibiotics in children with exacerbations of non-cystic fibrosis bronchiectasis: A pilot study. Pediatr Respirol Crit Care Med 2026;XX:XX-XX. 5. Sibanda D, Singleton R, Clark J, Desnoyers C, Hodges E, Day G, et al. Adult outcomes of childhood bronchiectasis. Int J Circumpolar Health 2020;79:1731059 "
  • Stephanie Yerkovich Speaker Australia
    Protracted bacterial bronchitis (PBB) is a common cause of chronic wet cough in children and an important contributor to respiratory morbidity. Increasing evidence suggests that PBB and bronchiectasis are not distinct disease entities but instead represent different stages along a spectrum. PBB and bronchiectasis share many clinical, microbiological and immunological features. Furthermore, persistent bacterial infection, neutrophilic airway inflammation and immune responses provide mechanistic links between PBB and bronchiectasis. Longitudinal follow-up studies have also demonstrated that recurrent PBB and persistent lower airway infection are associated with an increased risk of developing bronchiectasis, highlighting the importance of early recognition and effective management. Integrating advances in basic, translational, and clinical research, will improve the understanding of the PBB-bronchiectasis continuum. Identifying children at risk of developing bronchiectasis will allow targeted, implementable interventions to prevent irreversible lung disease and improve respiratory outcomes.
  • Q&A
Ballroom 2, Lower Ground Floor